Case Presentations

Success Stories

Patients receiving treatment guided by TumorGraft testing have responded to their individualized treatments and seen a reduction in the size of their tumors, with durable remissions. Tumors that have been treated successfully using TumorGraft testing include cancers of the colon, pancreas, stomach, esophagus, lung and breast, as well as sarcomas and others.

Treatments included single-agent chemotherapy drugs, combination chemotherapy drugs, targeted biological drugs and investigational drugs in clinical trials. In many of these cases, Champions Oncology successfully identified several treatments that were used one after another to provide additional clinical benefits.

Gastroesophageal CancerMetastatic Colorectal CancerMetastatic LeiomyosarcomaLung Cancer

Gastroesophageal cancer:

A 56-year-old male with metastatic gastroesophageal cancer who had two prior regimens

The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.

chart-gastroesophageal-02  chart-gastroesophageal-01

Case study conclusions
  • The patient responded to four courses of TumorGraft-guided therapy
  • Survival lasted 32 months in late-line therapy.  The patient died of an infection while the tumor remained stable.

 Download a PDF of this case study

 

Metastatic Colorectal Cancer:

A 44-year-old female diagnosed with metastatic colorectal cancer who had two prior regimens.

The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.

chart-thumb-metastatic-colorectal

  • Patient’s pelvic tumor regressed by 60 percent following irinotecan monotherapy (partial response) even though the patient had received FOLFIRI in the past
    • The patient had resolution of the hydronephrosis
    • Patient had a partial response lasting longer than 50 months
  • Additional drug testing revealed that maximal response in the patient’s TumorGraft was achieved with laptinib combined with capecitabine (fourth line of treatment)
    • Patient’s tumor regressed to a partial response, which lasted six additional months
Case study conclusions
  • The TumorGraft revealed that the patient would respond best to one of the three combined treatments she had received previously
  • Patient responded to two courses of Champions-guided treatment
  • Because the tumor had reoccurred and metastasized after FOLFIRI treatment, the patient would have likely never been retreated with irinotecan if not for TumorGraft testing

Download a PDF of this case study

A 55-year-old female diagnosed with abdominal metastatic leiomyosarcoma who had three prior regimens.

The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.

chart-thumb-metastatic-leiomyosarcoma

  • Triple drug therapy, consisting of gemcitabine, docetaxel and bevacizumab) was selected for fourth-line treatment and resulted in a 50 percent reduction in tumor mass (partial response)
    • Patient remained in partial response for nine months
  • Additional drug testing revealed that maximal response in the patient’s TumorGraft was achieved with capecitabine combined with temozolomide (fifth line of treatment)
    • This treatment was not a standard one for leiomyosarcoma
    • The patient’s tumor regressed (partial response) for six more months
Case study conclusions
  • Patient responded to two courses of Champions-guided treatment
  • One of the combinations found was novel for the treatment of leiomyosarcoma
  • Patient lived 15 months on late-line therapy

 Download a PDF of this case study

Lung Cancer

A 50-year-old male diagnosed with stage IV non-small-cell lung cancer who had received treatment with two prior chemotherapy regimens.

The following demonstrates the TumorGraft response to drug-testing-informed treatment decisions.

chart-thumb-lung

  • The patient’s physician elected to treat patient with third-line treatment, consisting of sorafenib, bevacizumab and irinotecan, based on TumorGraft results
  • Patient’s tumor regressed (partial response) for nine months
  • Triple therapy was then discontinued due to side effects
  • Sorafenib alone was continued and delivered another six months of remission
Case study conclusions
  • Patient responded to one course of Champions-guided treatment
  • Patient lived 15 months on late-line therapy

Download a PDF of this case study

To download our prospectus, which includes a comprehensive overview of the TumorGraft process and recently updated case studies, please complete the form below.